Along these lines, a recent case report analyzed drug response of a metastatic non-small-cell lung cancer (NSCLC) patient, whose tumor lacked PTEN expression: the authors described immunotherapy-resistance despite high levels of PD-L1 expression, while the tumor responded to rapamycin analogs [120]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.